HOUGEN ELIZABETH L 4
4 · IONIS PHARMACEUTICALS INC · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Ionis (IONS) CFO Elizabeth Hougen Sells Shares, Receives Award
What Happened
Elizabeth L. Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals (IONS), had 13,562 performance-based restricted stock units (PRSUs) vest on Jan 29, 2026, and sold 6,988 shares in an open-market transaction on Jan 30, 2026. The sale generated approximately $581,702 at a weighted-average price of $83.24 per share. The PRSU payout was 167.27% of target based on relative total shareholder return vs. a peer group.
Key Details
- Award vesting: 13,562 shares vested on 2026-01-29 (PRSUs from a Jan 18, 2023 grant; payout = 167.27% of target). (Footnote F1)
- Sale: 6,988 shares disposed on 2026-01-30, weighted-average price $83.24, proceeds ≈ $581,702. Sale prices ranged $83.11–$83.32. (Footnote F2)
- Filing: Form 4 filed 2026-02-02 — within the two-business-day reporting window (timely).
- Shares owned after transaction: Not specified in the information provided on this filing.
- Notable notes: Vesting was performance-based (PRSUs). No 10b5-1 plan, tax-withholding, or late-filing flag disclosed in the provided filing.
Context
The Jan 29 entry was a compensation event (PRSUs vesting based on performance), not a market purchase. The subsequent open-market sale the next day appears to be a disposition of shares (often routine following vesting), but the filing is factual only and does not state motivation. Retail investors often view purchases as stronger signals than routine sales or compensation vesting; this filing documents a standard vest-and-partial-sell sequence.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-29+13,562→ 139,869 total - Sale
Common Stock
[F2]2026-01-30$83.24/sh−6,988$581,702→ 132,881 total
Footnotes (2)
- [F1]Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.11 to $83.32 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.